Background: Hybrid positron emission tomography (PET)/magnetic resonance (MR) is an emerging imaging modality with great potential to provide complementary data acquired at the same time, under the same physiological conditions. The aim of this study was to evaluate the prognostic value of hybrid ¹⁸F-fluorodeoxyglucose (FDG) PET/MR in patients with differentiated thyroid cancer (DTC) who underwent total thyroidectomy and radioactive iodine therapy for suspicion of disease relapse. Methods: Between November 2015 and February 2017, 55 patients underwent hybrid ¹⁸F-FDG PET/MR. Assessment of positive MR was made considering all sequences in terms of malignancy based on the morphological T2-weighted features and the presence of restricted diffusivity on diffusion-weighted imaging images and both needed to be positive on the same lesion. Both foci with abnormal ¹⁸F-FDG uptake, which corresponded to tissue abnormalities on the MR, and tracer accumulation, which did not correspond to normal morphological structures, were considered positive. Results: During follow-up (mean 42 ± 27 months), 29 patients (53%) had disease recurrence. In the Cox univariate regression analysis age, serum Tg level ≥ 2 ng/mL, positive short tau inversion recovery (STIR), and positive PET were significant predictors of DTC recurrence. Kaplan–Meier survival analyses showed that patients with Tg ≥ 2 ng/mL had poorer outcomes compared to those with serum Tg level < 2 ng/mL (p < 0.05). Similarly, patients with positive STIR and positive PET had a worst outcome compared to those with negative STIR (p < 0.05) and negative PET (p < 0.005). Survival analysis performed in the subgroup of 36 subjects with Tg level ≥ 2 ng/mL revealed that patients with positive PET had a worst outcome compared to those with negative PET (p < 0.05). Conclusions: Age, serum Tg level ≥ 2 ng/mL, positive STIR, and positive ¹⁸F-FDG PET were significant predictors of DTC recurrence. However, the serum Tg level was the only independent predictor of DTC. Hybrid PET/MR imaging may have the potential to improve the information content of one modality with the other and would offer new opportunities in patients with DTC. Thus, further studies in a larger patient population are needed to understand the additional value of ¹⁸F-FDG PET/MR in patients with DTC.

This study reports the development of peptide-based hydrogels for the encapsulation and controlled release of peptide nucleic acids in drug delivery applications. Ultrashort aromatic peptides, such as Fmoc-FF, self-assemble into biocompatible hydrogels with nanostructured architectures. The functionalization of tripeptides (Fmoc-FFK and Fmoc-FFC) with lysine (K) or cysteine (C) enables electrostatic or covalent interactions with model PNAs engineered with glutamic acid or cysteine residues, respectively. Hydrogels were polymerized in situ in the presence of PNAs, and component ratios were systematically varied to optimize mechanical properties, loading efficiency, and release kinetics. The formulations obtained with a 1/10 ratio of Fmoc-FF(K or C)/Fmoc-FF provided an optimal balance between structural integrity and delivery performance. All hydrogel formulations demonstrated high stiffness (G′ > 19,000 Pa), excellent water retention, and minimal swelling under physiological conditions (ΔW < 4%). The release studies over 10 days showed that electrostatic loading enabled faster and higher release (up to 90%), while covalent bonding resulted in slower, sustained delivery (~15%). These findings highlight the tunability of the hydrogel system for diverse therapeutic applications.

This study investigates the use of peptide-based hydrogels as scaffolds for the encapsula-tion and delivery of Peptide Nucleic Acids (PNAs) in drug delivery applications. Ultra-short aromatic peptide-based hydrogels (HGs), such as Fmoc-FF (Nα-fluorenyl methox-ycarbonyl-diphenylalanine), provide an ideal platform for encapsulating biomolecules due to their biocompatibility, self-assembling nature, and ability to form stable, nanostructured networks. The functionalization of these hydrogels with Fmoc-FFX tripep-tides—where X is cysteine (C) or lysine (K)—enhances their ability to interact with PNA sequences. Model four-bases PNA, functionalized with cysteine (C) or glutamic acid (E) residues at the C-terminus, facilitate covalent or electrostatic interactions with the hydro-gel matrix, improving encapsulation efficiency and stabilizing the PNAs. We systemati-cally optimized the composition and ratios of hydrogel components and PNAs to enhance encapsulation efficiency, structural stability, and controlled release profiles. The resulting hydrogels were thoroughly characterized using High-Performance Liquid Chromatog-raphy (HPLC), Electrospray Ionization Mass Spectrometry (ESI-MS), Circular Dichroism (CD), rheology, Fourier-Transform Infrared (FT-IR) spectroscopy, Scanning Electron Mi-croscopy (SEM), Proton Nuclear Magnetic Resonance (¹H-NMR), as well as optical and fluorescence microscopy. Our results demonstrate the potential of these hydrogels as highly effective platforms for stabilizing and delivering PNAs, offering promising pro-spects for the development of innovative nucleic acid-based therapies.

CircRNAs are covalently closed ncRNAs originating through back splicing; their expression is finely regulated, displaying specific patterns across different cell types, tissues, and developmental stages. While the molecular functions of circRNAs are not completely elucidated, their regulatory involvement in physiological processes is well established, alongside their dysregulation in several human disorders. These features, together with their higher stability compared to other ncRNAs, make this class of molecules promising theragnostic agents, particularly in biomarker discovery. Accordingly, it is crucial to develop and standardize experimental strategies that improve circRNA analysis, ensuring accurate and effective isolation of these molecules. In biomarker discovery, selecting the appropriate biological matrix is critical; whole blood is often preferred for its accessibility and minimally invasive collection. Because circRNAs are present in human peripheral blood and show promise as disease theragnostic biomarkers, we established a preliminary workflow tailored to isolate and analyze circRNAs from whole blood. The promising effectiveness and robustness of this workflow were demonstrated by qPCR analysis, suggesting highly reproducible detection and reliability in isolating and analyzing circRNAs. This, together with their stability and specific expression profiles, supports the utility of circRNAs in biomarker discovery and advanced circRNA research and contributes to accelerating their future integration into theragnostic applications in clinical settings.

Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. For this reason, initial diagnosis, prognosis, and targeted therapy of NSCLC represent very attractive areas of study. Aptamers are single-stranded nucleic acids (RNA or DNA) generated through Systematic Evolution of Ligands by Exponential Enrichment (SELEX); they are able to bind to a molecular target with high affinity and specificity. Thanks to their intrinsic nucleic acid properties, they can be easily modified and optimized to enhance target binding and their half-life; moreover, they exhibit no immunogenicity and toxicity. Due to this, many aptamers have just been selected against NSCLC biomarkers and provide specific imaging agents to improve the diagnosis of this type of cancer. However, despite the promising results in preclinical studies, the application of aptamers in NSCLC diagnosis is still in its early stages, mainly due to the limited literature in the research world, the dominance of antibodies in the pharmaceutical market and the challenge of target identification. Consequently, this appears to be a temporary issue, and aptamers could see increasing application in the future; thus, we performed a review aimed at summarizing current knowledge on the new promising DNA and RNA aptamer-based molecules for NSCLC diagnosis. All studies from 2000 were included and investigated. Our findings showed that several DNA and RNA aptamers are promising diagnostic tools for NSCLC management.